‘We’re increasingly seeing incidents where alert fatigue has been identified as a contributing factor. It’s not that there wasn’t an alert in place, but that it was lost among the other alerts the clinician saw,’ Prof Baysari says.
Creating a tailored, individualised approach is the key to helping patients safely deprescribe from opioids.
This National Pain Week (25 July– 1 August) Australian Pharmacist explores how to help patients cope with chronic pain.
As new pharmacist prescribing pilots and models continue to be introduced, here's a look at the history of prescribing and where it’s headed.
The Medical Services Advisory Committee's support for funding embedded pharmacists in Aboriginal Health Services could be a game changer.
All pharmacists can soon dispense MS-2 Step, following a landmark decision by the Therapeutic Goods Administration.
Changes to the Opioid Dependence Treatment program could make long-acting injectable buprenorphine the best option for many people.
All the new initiatives, funding schemes and Pharmaceutical Benefits Scheme (PBS) listings that kicked into gear on 1 July 2023.
The new Opioid Dependence Treatment Program kicks off on 1 July. Here's the steps you need to take before, during and after the transition.
The 60-day dispensing policy is predicted to have enormous impacts on community pharmacy and vulnerable Australians.
The recent death of a healthy 3-year-old boy from influenza is a reminder of the dangers of the virus and the importance of vaccination.
